» Articles » PMID: 20170751

Rapid Response to Cognitive Behavior Therapy Predicts Treatment Outcome in Patients with Irritable Bowel Syndrome

Overview
Specialty Gastroenterology
Date 2010 Feb 23
PMID 20170751
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Cognitive behavior therapy (CBT) is an empirically validated treatment for irritable bowel syndrome (IBS), yet it is unclear for whom and under what circumstances it is most effective. We investigated whether patients who achieved a positive response soon after CBT onset (by week 4), termed rapid responders (RRs), maintain treatment gains compared with non-rapid responders. We also characterized the psychosocial profile of RRs on clinically relevant variables (eg, health status, IBS symptom severity, distress).

Methods: The study included 71 individuals (age, 18-70 y) whose IBS symptoms were consistent with Rome II criteria and were of at least moderate severity. Patients were assigned randomly to undergo a wait list control; 10 weekly 1-hour sessions of CBT; or four 1-hour CBT sessions over 10 weeks. RRs were classified as patients who reported adequate relief of pain, adequate relief of bowel symptoms, and a decrease in total IBS severity scores of 50 or greater by week 4.

Results: Of patients undergoing CBT, 30% were RRs; 90% to 95% of the RRs maintained gains at the immediate and 3-month follow-up examinations. Although the RRs reported more severe IBS symptoms at baseline, they achieved more substantial, sustained IBS symptom reduction than non-rapid responders. Both dosages of CBT had comparable rates of RR.

Conclusions: A significant proportion of IBS patients treated with CBT have a positive response within 4 weeks of treatment; these patients are more likely to maintain treatment gains than patients without a rapid response. A rapid response is not contingent on the amount of face-to-face contact with a clinician.

Citing Articles

Factors That Predict Magnitude, Timing, and Persistence of Placebo-Like Response in Patients With Irritable Bowel Syndrome.

Lackner J, Quigley B, Zilcha-Mano S, Radziwon C, Krasner S, Gudleski G Gastro Hep Adv. 2024; 3(2):221-229.

PMID: 38456188 PMC: 10919349. DOI: 10.1016/j.gastha.2023.10.003.


The role of mind body interventions in the treatment of irritable bowel syndrome and fibromyalgia.

Islam Z, DSilva A, Raman M, Nasser Y Front Psychiatry. 2023; 13:1076763.

PMID: 36620663 PMC: 9814478. DOI: 10.3389/fpsyt.2022.1076763.


Study protocol and methods for Easing Pelvic Pain Interventions Clinical Research Program (EPPIC): a randomized clinical trial of brief, low-intensity, transdiagnostic cognitive behavioral therapy vs education/support for urologic chronic pelvic....

Lackner J, Jaccard J, Quigley B, Ablove T, Danforth T, Firth R Trials. 2022; 23(1):651.

PMID: 35964133 PMC: 9375413. DOI: 10.1186/s13063-022-06554-9.


Brief and Telehealth Acceptance and Commitment Therapy (ACT) Interventions for Stress in Inflammatory Bowel Disease (IBD): A Series of Single Case Experimental Design (SCED) Studies.

Lavelle J, Storan D, Eswara Murthy V, De Dominicis N, Mulcahy H, McHugh L J Clin Med. 2022; 11(10).

PMID: 35628884 PMC: 9145285. DOI: 10.3390/jcm11102757.


Specific and common mediators of gastrointestinal symptom improvement in patients undergoing education/support vs. cognitive behavioral therapy for irritable bowel syndrome.

Lackner J, Jaccard J J Consult Clin Psychol. 2021; 89(5):435-453.

PMID: 34124927 PMC: 9380705. DOI: 10.1037/ccp0000648.


References
1.
Mulak A, Bonaz B . Irritable bowel syndrome: a model of the brain-gut interactions. Med Sci Monit. 2004; 10(4):RA55-62. View

2.
Lackner J, Mesmer C, Morley S, Dowzer C, Hamilton S . Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis. J Consult Clin Psychol. 2004; 72(6):1100-13. DOI: 10.1037/0022-006X.72.6.1100. View

3.
Howard K, Kopta S, Krause M, Orlinsky D . The dose-effect relationship in psychotherapy. Am Psychol. 1986; 41(2):159-64. View

4.
Lackner J, Jaccard J, Krasner S, Katz L, Gudleski G, Holroyd K . Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. Clin Gastroenterol Hepatol. 2008; 6(8):899-906. PMC: 2630498. DOI: 10.1016/j.cgh.2008.03.004. View

5.
Camilleri M, Chey W, Mayer E, Northcutt A, Heath A, Dukes G . A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001; 161(14):1733-40. DOI: 10.1001/archinte.161.14.1733. View